Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Lymphangiogenesis Modulation and Metastasis Inhibition in Oncology and Lymphatic Disorders.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for VEGFC drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | VEGF-C Wild-Type & VEGF-C156S Mutant Protein High purity (>95%), Endotoxin <1EU/μg. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View VEGFC Products |
| Gene Delivery | VEGF-C Promise-ORF / Lentivirus Full-length ORF with native signal peptide for secreted expression. Endotoxin Controlled. |
View VEGFC Products |
| Benchmark Ab | Anti-VEGF-C (Sequence of IMC-3C5) Recombinant positive control for neutralization assays. Sequence Verified. |
View VEGFC Products |
| Validator | VEGF-C siRNA Set For knockdown verification in lymphatic endothelial cells. Sequence Verified. |
View VEGFC Products |
| Related Target: VEGFR-3 | FLT4 / VEGFR-3 Receptor Protein Primary receptor for VEGF-C binding assays. ECD-Fc fusion, >95% purity. |
View VEGFR-3 Products |
| Related Target: VEGF-D | VEGF-D Protein Synergistic lymphangiogenesis factor; compensatory pathway analysis. |
View VEGFD Products |
| Related Target: VEGFR-2 | KDR / VEGFR-2 Receptor Protein Secondary receptor; essential for selectivity counter-screening. |
View VEGFR-2 Products |
Critical Assay Challenges & The TarMart Advantage
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Pro-form vs Mature Form Discrimination | Both pro-VEGF-C (full-length) and mature ΔNΔC-VEGF-C (fully processed) variants available; Sequence Verified for processing site integrity |
| VEGFR-3 vs VEGFR-2 Selectivity Profiling | Human VEGFR-3 (FLT4) and VEGFR-2 (KDR) ECD-Fc proteins strictly verified by mass spec; >95% purity for accurate Kd determination |
| Agonist Stability (Sub-Q Formulation) | VEGF-C156S mutant (Cys156Ser, protease-resistant, stable) available; Theoretical MW confirmed; High concentration (>50 mg/mL) compatibility |
| Cross-species Cyno/Mouse Translation | Human, Mouse, and Cynomolgus VEGF-C orthologs with >95% purity; Identical endotoxin control (<1EU/μg) across species |
| Lack of Controls | Clinical Benchmark Antibodies (IMC-3C5 biosimilar) included for assay standardization |
| False Positives in Binding Assays | Validated siRNA included for specificity checks; Target knockdown verification |
| Subfamily counter screening (vs VEGF-A, VEGF-D) | Homolog panel proteins strictly verified by mass spec and sequence validation |
Live VEGFC R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The VEGF-C therapeutic landscape is bifurcated between oncology (antagonism to block lymphatic metastasis) and lymphatic dysfunction (agonism for lymphoedema treatment). First-generation anti-VEGF-C antibodies (e.g., IMC-3C5) are advancing into Phase II combinations with immune checkpoint inhibitors. Simultaneously, engineered VEGF-C variants (VEGF-C156S) for primary and secondary lymphoedema are entering clinical trials. The next wave of R&D is targeting bispecific modalities that simultaneously modulate VEGF-C and VEGF-A pathways to normalize tumor vasculature while preserving lymphatic drainage, and combination therapies to overcome primary anti-VEGFA resistance in solid tumors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Anti-VEGF-C Monoclonal Antibody | Imara/Incyte (IMC-3C5), Regeneron | Solid Tumors (metastasis prevention) | VEGFR-3 Blocking Assay (Need high-purity VEGF-C & VEGFR-3 ECD-Fc) |
| VEGF-C/D Receptor Trap | Opthea (OPT-302) | Diabetic Retinopathy, wAMD | Binding Kinetics (Native Glycosylated Antigens) |
| VEGF-C Agonist Protein | VEGF-C156S (Lymfactin), University of Helsinki | Primary/Secondary Lymphoedema | Receptor Selectivity Assay (VEGFR-3 vs VEGFR-2 binding affinity) |
| Bispecific (VEGF-C/VEGF-A, VEGF-C/PD-1) | Various Biotech | Refractory Cancers, Immunotherapy combinations | Heterodimer Validation, Epitope Mapping (Need cross-reactive Abs) |
| Gene Therapy (AAV-VEGF-C) | Academic groups | Cancer metastasis, Lymphoedema | Expression validation, Processing efficiency (Need ORF Lentivirus) |